26 January 2010 - Leverton Licence Holdings (LLH) has invested in a research project - which will be undertaken by Polytherics and Cantab Biopharmaceuticals - to develop a biopharmaceutical molecule.
Celtic Pharma Holdings Advisors (CPHA), advisor to Celtic Pharma Holdings II (CP2), and Polytherics made the announcement that LLH, a wholly owned subsidiary of CP2, had invested in the research programme.
Cantab, based in Cambridge, UK, is also a wholly owned subsidiary of CP2.
Polytherics will receive an upfront payment and technical support for the research, while LLH may elect to submit two further proteins for research under the collaboration.
